Veracyte

09/04/2026

Over the last three decades, advances in prostate cancer screening and molecular testing have led to significant improvements in early detection and patient outcomes. However, a prostate cancer diagnosis is often only the beginning of a long, personal journey.

On that path, patients face difficult questions, like:

🔹 What does my diagnosis mean?

🔹 How aggressive is my cancer?

🔹 What are my treatment options?

🔹 What are the risks and benefits?

🔹 Is more treatment likely to help me?

🔹 Could some treatment be avoided?

In honor of Prostate Cancer Awareness Month, we wrote an article that takes a closer look at what comes after diagnosis, addressing the patient experience and some important clinical considerations along the way. As a central part of that discussion, we address how advancements in genomic testing are helping to inform more personalized conversations about care.

🔗 Read our thoughts here - https://www.veracyte.com/company/blog/from-awareness-to-answers-helping-personalize-care-this-prostate-cancer-awareness-month/

At Veracyte, we believe patients deserve answers that reflect the biology of their disease. Through the Decipher® Prostate Genomic Classifier, we are working to help clinicians and patients navigate complex prostate cancer treatment choices with genomic insights supported by a growing body of research.



Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

Honoring Prostate Cancer Awareness Month 2026, we share how prostate cancer genomic testing and new Decipher Prostate research are helping guide treatment.

05/29/2026

We are proud to announce results from the landmark independent OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) trial, led by University College London (UCL).

The results, which will be presented at the ASCO 2026 Annual Meeting, conclude that the Prosigna® Breast Risk of Recurrence (ROR) test safely guides adjuvant chemotherapy decisions in patients with early-stage, estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer.

| Impact |

The study shows for the first time, based on the Prosigna test results, that more than 2/3 of patients with clinically high-risk node-positive breast cancer, including premenopausal women and patients with 4 to 9 positive nodes, could safely forgo chemotherapy and its long-term physical and emotional side effects without compromising outcomes.

For decades, chemotherapy decisions have relied on clinical factors alone such as age, tumor size, and lymph node status. Today, many node-positive breast cancer patients still receive chemotherapy as standard of care with up to 43% of breast cancer survivors experiencing persistent nerve damage years after chemotherapy.*

The Prosigna test determines a patient's ROR score, estimates the 10-year probability of distant recurrence, and identifies patients who can benefit from chemotherapy and those who may safely avoid it.

The OPTIMA trial results deliver practice-changing evidence to inform more personalized chemotherapy decision-making. These results show that the Prosigna test can accurately predict chemotherapy benefit and guide safe de-escalation across the broadest set of patients with clinically high-risk breast cancer to-date.

Prof. Rob Stein, Lead Investigator, from UCL will present the OPTIMA trial results at the ASCO 2026 Annual Meeting.

| Presentation Details |

📅 Date and Time: Saturday, May 30 at 1:15 PM CDT

📍 Location: Breast Cancer – Local/Regional/Adjuvant, Hall B1, Abstract 500

| Resources |

📄 Read full press release - https://investor.veracyte.com/news-releases/news-release-details/landmark-optima-trial-delivers-practice-changing-evidence

🔗 Event information - https://www.veracyte.com/company/events-upcoming/asco-2026-prosigna/

🧬 More on the OPTIMA trial - https://optimabreaststudy.com/

| References |

(*) Kamgar M, et al. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Medicine. 2021;10(19):6666-6676.

This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

05/28/2026

Veracyte is a proud supporter of Conquer Cancer Foundation, a non-profit organization that funds cancer research, education, and other vital programs to improve patient outcomes.

As part of their mission to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer, they provide funding to support physician-scientists during the early stages of their careers through their Young Investigator Awards (YIA) program.

The Conquer Cancer® - Veracyte Endowed Young Investigator Award in Breast Cancer Genomics will be awarded each year.

Today, we are excited to congratulate the first recipient: Alexandra Bili Newman, M.D., The University of Texas MD Anderson Cancer Center!

Dr. Bili Newman is a second-year Hematology-Oncology fellow at MD Anderson Cancer Center in Houston, TX, with a clinical and research focus in Breast Oncology.

Her upcoming YIA project focuses on the role of post-transcriptional PTEN loss as a predictive biomarker of response to PI3K targeted agents in advanced hormone-receptor positive breast cancer.

Join us in congratulating Alexandra and the other Conquer Cancer grant and award recipients.

05/27/2026

The OPTIMA phase III trial evaluated whether the Prosigna® Breast Risk of Recurrence test can help guide chemotherapy decisions for women with early-stage breast cancer. First results will be presented Saturday, May 30 at ASCO 2026 in Chicago.

See the latest coverage in Reuters by Nancy Lapid: https://www.reuters.com/business/healthcare-pharmaceuticals/veracyte-genomic-test-identifies-breast-cancer-patients-who-can-skip-chemo-2026-05-27/

Join us at ASCO 2026: https://www.veracyte.com/company/events-upcoming/asco-2026-prosigna/

This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information: https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

05/22/2026

May is Bladder Cancer Awareness Month, a moment to recognize the people behind every diagnosis: patients navigating difficult decisions, the friends and family offering support along the way, and the healthcare professionals dedicated to delivering the best possible care.

🔹 Bladder cancer is one of the most common cancers worldwide

🔹 It does not behave the same way in every person, and differences in tumor biology can influence how the disease progresses and how it is treated

🔹 Ongoing advances from the research community continue to deepen our understanding and help guide more personalized treatment decisions

At Veracyte, our commitment to advancing bladder cancer science is rooted in evidence, innovation, and collaboration. The Decipher Bladder test is a molecular subtyping tool that reveals underlying biological insights to help bring clarity to bladder cancer treatment decisions.

Read our latest blog to learn how molecular insights are helping guide more personalized bladder cancer care: https://www.veracyte.com/company/blog/the-future-of-personalized-bladder-cancer-care/

Note: this information contains forward-looking statements - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/

05/21/2026

Data from two significant phase III clinical trials using our Prosigna Breast and Decipher Prostate tests will be presented at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026), taking place May 29 through June 2 in Chicago.

The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte's genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer.

🔹 Prosigna Breast: The results from the OPTIMA study will address a key clinical question: which breast cancer patients would benefit from chemotherapy, and which may be able to safely avoid it – and its lasting side effects.

🔹 Decipher Prostate: The independent analysis of results from the ENZAMET trial will assess the ability of the Decipher Prostate test to identify which patients with metastatic prostate cancer are most likely to benefit from adding chemotherapy to their treatment plan.

Read the full press release - https://investor.veracyte.com/news-releases/news-release-details/optima-trial-results-be-presented-asco-provide-new-evidence

Event information - https://www.veracyte.com/company/event/asco-2026/

Learn more about Prosigna Breast -https://www.veracyte.com/tests/prosigna-breast/

Learn more about Decipher Prostate - https://www.veracyte.com/tests/decipher-prostate/

Note: this information contains forward-looking statements - https://www.veracyte.com/legal/cautionary-note-regarding-forward-looking-statements/